Financial authorities again cut the disclosure of pharmaceutical and bio companies. The Korea Exchange prepared the 'Inclusive Disclosure Guidelines for Pharmaceuticals and Bio-Industry' and recommended that specific disclosure cases be followed and followed in accordance with industry characteristics. The intention is to encourage investors to provide detailed information on important management matters in order to make reasonable investment decisions.

In detail, listed companies should disclose the facts and results of their application for a clinical trial plan. Even if a previously approved clinical trial plan has changed, it needs to be disclosed. Even when the trial is suspended or terminated, com